Oxford Medical Products has developed Sirona, a drug-free, once daily hydrogel pill that is in clinical development for the treatment of overweight and obesity. Once swallowed and in the stomach, Sirona expands rapidly to reduce the available volume of the stomach, which provides sustained appetite suppression and reduces calorie intake to drive weight loss. Sirona remains in the stomach for several days, providing around the clock appetite suppression, before breaking into smaller pieces and passing naturally. Sirona has completed its second UK clinical trial and is pending regulatory approval in Europe.
Weight management
Sirona has 3 key target markets:
Overweight (BMI 25-30): Individuals living with overweight are largely ineligible for GLP-1 therapies such as Wegovy and Mounjaro and do not need their extremity. Sirona is ideally positioned as an early intervention to prevent these individuals progressing into obesity.
Drug-free alternative to GLP-1s: Sirona provides a treatment option for individuals who cannot or do not want to use pharmacotherapy for their weight loss.
Weight Maintenance post GLP-1 Therapy: Sirona is uniquely positioned to support individuals transitioning off GLP-1 treatments, helping to prevent or minimize weight regain, allowing them to maintain their new weight long term.
